# Pizarra — PT-pseudo_34647958aba3 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_34647958aba3
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 7.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.121 ng/mL²
  - PSA velocity: 2.45 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 63.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.0 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7.6 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 63 mL. DRE nodus. csPCa 0.00.

Vitals: weight 67 kg, height 179 cm, BMI 20.9, BP 128/95 mmHg, HR 83 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2021).

Chief complaint: Clinical review requested due to escalating prostate-specific antigen values alongside established biopsy history.

History: This semi-retired harbour pilot, aged 65, has maintained routine monitoring since his initial biopsy uncovered low-grade disease. He shares a household with his spouse and experiences negligible lower urinary tract symptoms, scoring a mere 4 on the IPSS questionnaire. His medical routine includes periodic visits to a sleep clinic for suspected obstructive sleep apnoea, alongside a recently completed chest radiograph. Daily activities remain active, featuring regular gardening and a modest alcohol intake of approximately nine units per week. A complete cessation of tobacco occurred in 2021, marking the end of a 34 pack-year consumption. Osteoarthritic discomfort remains controlled with occasional paracetamol, while his appointment scheduling consistently favors mornings to accommodate public transit availability.

Physical examination: DRE — texture: firm; mobility: fixed; asymmetry: prominent nodule localized to the left peripheral zone. Systemic assessment reveals normal vital parameters without evidence of disseminated disease.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 9 units / week; exercise Gardening, no structured exercise; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Sleep clinic — suspected obstructive sleep apnoea; Radiology — chest X-ray (routine).
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.20   (95% CI 0.08-0.81)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.9 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=7.6, age=65.0, psad=0.121, dre_ord=1.0, vol=63.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5.0, PSA=7.6, prior biopsy positive, csPCa probability=0.0) and failed to incorporate the clinical context of the rising PSA velocity (2.45 ng/mL/yr) and the specific PSA density (0.121 ng/mL²). It also did not weigh the DRE finding of a nodule, which is a physical finding that contradicts the low csPCa probability.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested 'NO BIOPSY' with a wide uncertainty interval (0.42 +/- 0.20). The wide aleatoric error (dA = 0.15) suggests the classifier is genuinely unable to distinguish between the two outcomes based on the limited input. Furthermore, the prior ignores the guideline criterion that states the decision must be based on retrieved documents, meaning the statistical suggestion is explicitly insufficient.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_34647958aba3", "radiology_report": "Radboud University Medical Centre | Radiology Division | 20 February 2025 | Multiparametric MRI of the Prostate\n\nClinical indication: Evaluation of a 65-year-old gentleman with a PSA of 7.6 ng/mL and a history of a prior positive biopsy.\n\nFINDINGS:\nThe gland occupies a volume of 63.0 mL. T2-weighted sequences highlight a sharply demarcated hypointense area, roughly 18 mm in diameter, located in the left peripheral zone spanning the base through the mid-gland. Diffusion-weighted imaging shows intense restriction with corresponding ADC hypointensity. Early, focal enhancement is apparent on the dynamic contrast sequences. Capsular integrity remains intact with no seminal vesicle involvement or extracapsular spread. Pelvic lymph nodes appear normal.\n\nIMPRESSION:\nPI-RADS 5 lesion within the left peripheral zone.\nProstate volume 63.0 mL, PSAD 0.121 ng/mL/mL.\ncsPCa predicted probability 0.0."}
get_psa_trend
{"case_id": "PT-pseudo_34647958aba3", "psa_trend": [{"date": "Oct 2022", "val": 1.7}, {"date": "Dec 2023", "val": 2.6}, {"date": "Feb 2025", "val": 7.6}]}
get_previous_notes
{"case_id": "PT-pseudo_34647958aba3", "previous_notes": [{"date": "05 Sep 2023", "author": "Dr. K. Bakker (GP)", "text": "A laboratory draw in December 2023 recorded a PSA of 4.9 ng/mL, reflecting an incremental increase from the 4.3 ng/mL baseline noted in October 2022. Due to the history of a previous positive biopsy, a urology referral was initiated for comprehensive evaluation. During that visit, standard hematologic panels and a digital rectal assessment were completed."}]}
get_lab_results
{"case_id": "PT-pseudo_34647958aba3", "laboratory_results": [{"name": "PSA", "val": "7.6 ng/mL", "date": "13 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.22 ng/mL", "date": "13 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "13 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "13 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.2 x10^9/L", "date": "13 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "222 x10^9/L", "date": "13 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "105 umol/L", "date": "13 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "13 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "16.2 nmol/L", "date": "13 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "74 U/L", "date": "13 Jan 2025", "flag": ""}, {"name": "LDH", "val": "175 U/L", "date": "13 Jan 2025", "flag": ""}]}
NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for this decision.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion (18 mm) in the left peripheral zone.
- PSA trend: Rising velocity of 2.45 ng/mL/yr, with PSA rising from 4.9 ng/mL (Dec 2023) to 7.6 ng/mL (Feb 2025).
- Previous notes: Patient was referred for comprehensive evaluation following a prior positive biopsy.
- Lab results: PSA is 7.6 ng/mL, and %Free PSA is 16%.
AGAINST sampling this patient now:
- mpMRI report: csPCa predicted probability 0.0.
- Lab results: %Free PSA is 16% (which is generally reassuring).
- Previous notes: No information on whether the prior biopsy grade was documented.
WHERE THIS LEANS
The high-risk PI-RADS 5 finding combined with a significant PSA velocity strongly argues for further tissue sampling to characterize the lesion, despite the low predicted csPCa probability.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the csPCa predicted probability is 0.0 and %Free PSA is 16%, the high PI-RADS 5 finding and the significant PSA velocity of 2.45 ng/mL/yr strongly argue for further tissue sampling to characterize the lesion. The prior positive biopsy status is noted, but the absence of a documented prior grade means the biopsy is necessary to determine if the lesion has changed, which is the key factor missing from the record.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
